Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Beyond The Mask: Innovation & Opportunities For CRNAs

The R vs. S Enigma: Ketamine Enantiomers and Their Distinct Actions

15 Jul 2025

Description

We dive into the latest research on ketamine's therapeutic potential, including its role in treating ischemic stroke, postoperative cognitive dysfunction (POCD), and PTSD. You'll hear how scientists are studying its effects on brain regions like the hippocampus and amygdala, as well as its impact on neuroinflammation, fear memory, and neurogenesis.   We'll also explore ketamine’s use in anesthesia, its interactions with drugs like oral morphine, and how it's monitored using tools like EEG. From molecular techniques like RT-qPCR and Western blotting to real-world applications—this episode breaks down the science driving ketamine's future in medicine.   Here’s some of what you’ll hear in this episode: 🧠 Ketamine’s impact on brain function, cognition, and EEG readings 🧬 NMDA receptors, BDNF, cytokines & other molecular targets 📉 How ketamine may raise delirium risk in cognitively impaired patients 🧪 In vitro studies on ketamine’s anti-inflammatory and anticancer potential 📊 Why EEG interpretation—not just BIS numbers—matters for patient safety   Visit us online: https://beyondthemaskpodcast.com/ The 1099 CRNA Institute: https://aana.com/1099 Get the CE Certificate here (and directly submit to the NBCRNA): https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246 Donate to Our Heart Your Hands here: https://www.ourheartsyourhands.org/donate 

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.